Pharmacy News EU

A report, ‘Factors associated with virological response to etravirine in nonnucleoside reverse transcriptase inhibitor-experienced HIV-1-infected patients,’ is newly published data in Antimicrobial Agents and Chemotherapy. "To identify factors associated with virological response (VR) to an etravirine (ETR)-based regimen, 243 patients previously treated with nonnucleoside reverse transcriptase inhibitors (NNRTIs) were studied. The impact of baseline HIV-1 RNA, CD4 cell count, past NNRTIs used, 57 NNRTI resistance mutations, genotypic sensitivity score (GSS) for nucleoside reverse transcriptase inhibitors (NRTIs) and protease inhibitors (PIs), and the number of new drugs used with ETR for the first time on the VR to an ETR regimen were investigated," scientists writing in the journal Antimicrobial Agents and Chemotherapy report (see also Antiretrovirals).
"Among the 243 patients, the median baseline HIV-1 RNA level was 4.4 log(10) copies/ml (interquartile range [IQR], 3.7 to 4.9) and the median CD4 count was 175 cells/mm(3) (IQR, 69 to 312). Patients had been previously exposed to a median of 6 NRTIs, 1, NNRTI, and 5 PIs. Overall, 82% of patients achieved a VR at month 2, as defined by a decrease of at least 1.5 log(10) copies/ml and/or HIV-1 RNA level of <50 copies/ml. No difference in VR was observed between patients receiving or not a boosted PI in combination with ETR. Factors independently associated with a better VR to ETR were the number of drugs (among enfuvirtide, darunavir, or raltegravir) used for the first time in combination with ETR and the presence of the K103N mutation at baseline. Mutations Y181V and E138A were independently associated with poor VR, whereas no effect of the Y181C on VR was observed," wrote A.G. Marcelin and colleagues, Pitie-Salpetriere Hospital, Department of Virology.
The researchers concluded: "ETR was associated with high response rates in NNRTI-experienced patients in combination with other active drugs regardless of the therapeutic class used."
Marcelin and colleagues published their study in Antimicrobial Agents and Chemotherapy (Factors associated with virological response to etravirine in nonnucleoside reverse transcriptase inhibitor-experienced HIV-1-infected patients. Antimicrobial Agents and Chemotherapy, 2010;54(1):72-7).
Additional information can be obtained by contacting A.G. Marcelin, Pitie-Salpetriere Hospital, Dept. of Virology, 83 Boulevard de l’Hopital, 75013 Paris, France.
(c) 2010 Biotech Week via NewsRx.com